BioPharmSignal logoBioPharmSignal

Biotech News

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Praxis Precision Medicines (PRAX)Praxis Precision MedicinesEarnings

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. Food and Drug Administration (FDA) Pre-launch activities for ulixacaltamide and relutrigine are

Related news

PRAXPraxis Precision Medicines2026-08-06 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PRAXPraxis Precision Medicines2026-07-30 20:01 EST

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

BCLIBrainstorm Cell Therapeutics Inc.2026-08-14 20:00 EST

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

VTGNVistagen Therapeutics, Inc.2026-08-14 12:32 EST

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

ANVSAnnovis Bio2026-08-14 12:00 EST

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

TSHATaysha Gene Therapies2026-08-11 20:00 EST

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GANXGain Therapeutics2026-08-11 11:00 EST

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

ADXNAddex Therapeutics2026-06-25 05:00 EST

Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

CLNNClene Inc.2026-08-14 12:30 EST

Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights

NGENNervGen Pharma2026-08-13 11:30 EST

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

View all latest news

Praxis Precision Medicines

Precision Neuroscience Praxis Precision Medicines develops therapies for genetically and physiologically defined disorders of neuronal excitation. Its pipeline spans movement disorders and developmental epilepsies. Ulixacaltamide Ulixacaltamide is a small-molecule T-type calcium-channel modulator under FDA review for essential...

Recent company news

PRAXPraxis Precision Medicines2026-08-06 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PRAXPraxis Precision Medicines2026-08-04 20:01 EST

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRAXPraxis Precision Medicines2026-07-30 20:01 EST

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

PRAXPraxis Precision Medicines2026-07-07 12:00 EST

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

PRAXPraxis Precision Medicines2026-07-02 20:01 EST

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
375.94 USD
Market cap
7.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States